RELMADA THERAPEUTICS, INC. Cost of Revenue
RELMADA THERAPEUTICS, INC. (RLMD) reported Cost of Revenue of $685 for the 3-month period ending 2014-02-28, per its 10-Q filed 2014-04-15.
Discontinued › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2014-04-15
- RELMADA THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2014-02-28 was $685.00, a 63.25% decline year-over-year.
- RELMADA THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2013-11-30 was $1.69K, a 8.86% decline year-over-year.
- RELMADA THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2013-08-31 was $0.00, a 100.00% decline year-over-year.
- RELMADA THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2013-05-31 was $322.00, a 10.27% increase year-over-year.
- RELMADA THERAPEUTICS, INC. cost of goods and services sold for fiscal 2013 was $4.04K, a 30.40% decline from fiscal 2012.
- RELMADA THERAPEUTICS, INC. cost of goods and services sold for fiscal 2012 was $5.80K.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 21 month | Cost of Goods and Services Sold 24 month | Cost of Goods and Services Sold 27 month | Cost of Goods and Services Sold 30 month | Cost of Goods and Services Sold 33 month |
|---|---|---|---|---|---|---|---|---|---|
| 2014-02-28 | $685.00 10-Q · filed 2014-04-15 | $2.37K 10-Q · filed 2014-04-15 | $2.37K derived: sum of 3 quarters · filed 2014-04-15 | $2.69K derived: sum of 4 quarters · filed 2014-04-15 | $12.21K 10-Q · filed 2014-04-15 | ||||
| 2013-11-30 | $1.69K 10-Q · filed 2014-01-13 | $1.69K derived: sum of 2 quarters · filed 2014-01-13 | $2.01K derived: sum of 3 quarters · filed 2014-01-13 | $3.87K derived: sum of 4 quarters · filed 2014-04-15 | $11.52K 10-Q · filed 2014-01-13 | ||||
| 2013-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-16 | $322.00 derived: sum of 2 quarters · filed 2013-12-16 | $2.19K derived: sum of 3 quarters · filed 2014-04-15 | $4.04K 10-K · filed 2013-12-16 | $9.84K 10-K · filed 2013-12-16 | ||||
| 2013-05-31 | $322.00 10-Q · filed 2013-07-12 | $2.19K derived: sum of 2 quarters · filed 2014-04-15 | $4.04K 10-Q · filed 2013-07-12 | $5.03K derived: sum of 4 quarters · filed 2014-04-15 | $9.84K 10-Q · filed 2013-07-12 | ||||
| 2013-02-28 | $1.86K 10-Q · filed 2014-04-15 | $3.71K 10-Q · filed 2014-04-15 | $4.71K derived: sum of 3 quarters · filed 2014-04-15 | $5.00K derived: sum of 4 quarters · filed 2014-04-15 | $9.51K 10-Q · filed 2013-05-03 | ||||
| 2012-11-30 | $1.85K 10-Q · filed 2014-01-13 | $2.85K derived: sum of 2 quarters · filed 2014-01-13 | $3.14K derived: sum of 3 quarters · filed 2014-01-13 | $7.65K derived: sum of 4 quarters · filed 2014-01-13 | |||||
| 2012-08-31 | $998.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-16 | $1.29K derived: sum of 2 quarters · filed 2013-12-16 | $5.80K derived: sum of 3 quarters · filed 2013-12-16 | $5.80K 10-K · filed 2013-12-16 | |||||
| 2012-05-31 | $292.00 10-Q · filed 2013-07-12 | $4.80K derived: sum of 2 quarters · filed 2013-07-12 | $4.80K 10-Q · filed 2013-07-12 | ||||||
| 2012-02-29 | $4.51K 10-Q · filed 2013-05-03 | $4.51K 10-Q · filed 2013-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |